Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Femasys Inc (FEMY)

Femasys Inc (FEMY)
1.2800 -0.0100 (-0.78%) 11:32 ET [NASDAQ]
1.2500 x 7 1.2800 x 3
Realtime by (Cboe BZX)
1.2500 x 7 1.2800 x 3
Realtime 1.1871 -0.1029 (-7.98%) 09:25 ET
Quote Overview for Wed, Apr 2nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2200
Day High
1.3000
Open 1.2500
Previous Close 1.2900 1.2900
Volume 71,341 71,341
Avg Vol 624,073 624,073
Stochastic %K 13.21% 13.21%
Weighted Alpha -26.61 -26.61
5-Day Change -0.0850 (-6.37%) -0.0850 (-6.37%)
52-Week Range 0.8600 - 1.8400 0.8600 - 1.8400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,023
  • Shares Outstanding, K 27,150
  • Annual Sales, $ 1,630 K
  • Annual Income, $ -18,820 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta -2.55
  • Price/Sales 20.50
  • Price/Cash Flow N/A
  • Price/Book 12.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.17
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1801 +5.92%
on 03/31/25
Period Open: 1.5400
1.7599 -28.97%
on 03/20/25
-0.2900 (-18.83%)
since 03/03/25
3-Month
1.0400 +20.19%
on 01/28/25
Period Open: 1.1200
1.8000 -30.56%
on 02/21/25
+0.1300 (+11.61%)
since 01/03/25
52-Week
0.8600 +45.35%
on 11/19/24
Period Open: 1.8100
1.8400 -32.07%
on 04/04/24
-0.5600 (-30.94%)
since 04/03/24

Most Recent Stories

More News
Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic

The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.

VXF : 165.23 (-6.28%)
VTI : 266.18 (-4.23%)
FEMY : 1.2797 (-0.80%)
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

FEMY : 1.2797 (-0.80%)
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

FEMY : 1.2797 (-0.80%)
Q1 Virtual Investor Summit: On-Demand Presentations Now Live

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors...

SNANF : 0.1975 (+3.95%)
BRNS : 0.7600 (unch)
FEMY : 1.2797 (-0.80%)
PERF : 1.7050 (-3.67%)
DRTS : 2.50 (-3.10%)
GIFT : 1.8850 (-0.26%)
ROYIF : 0.0448 (+121.78%)
ZCAR : 3.95 (-20.14%)
CLNN : 2.81 (-6.33%)
MIND : 5.25 (-9.79%)
PYPD : 2.61 (-3.69%)
TOVX : 1.1400 (-3.39%)
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

FEMY : 1.2797 (-0.80%)
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

FEMY : 1.2797 (-0.80%)
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

FEMY : 1.2797 (-0.80%)
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

FEMY : 1.2797 (-0.80%)
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices

FEMY : 1.2797 (-0.80%)
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control

FEMY : 1.2797 (-0.80%)

Business Summary

Femasys Inc.is a biomedical company focused on transforming women's healthcare by developing novel solutions as well as providing significant clinical impact to address severely underserved areas. The company's lead product candidates offer FemBloc and FemaSeed. Femasys Inc. is based in ATLANTA.

See More

Key Turning Points

3rd Resistance Point 1.4800
2nd Resistance Point 1.4100
1st Resistance Point 1.3500
Last Price 1.2797
1st Support Level 1.2200
2nd Support Level 1.1500
3rd Support Level 1.0900

See More

52-Week High 1.8400
Fibonacci 61.8% 1.4656
Fibonacci 50% 1.3500
Last Price 1.2797
Fibonacci 38.2% 1.2344
52-Week Low 0.8600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades